Keyphrases
Bladder Cancer
100%
Patient-reported Outcomes
88%
Urothelial
63%
Therapeutic Vulnerabilities
59%
Antineoplastic Drugs
59%
Cancer Patients
49%
Denmark
37%
Electronic Patient-reported Outcome (ePRO)
35%
Copenhagen
33%
Clinical Practice
33%
Patient-Reported Outcomes Measurement Information System (PROMIS)
33%
HR Deficiency
29%
Daily Activities
29%
Metastatic Bladder Cancer
29%
Prostate Cancer Patients
29%
Bladder Cancer Therapy
29%
Fibroblast Growth Factor Receptor 1 (FGFR1)
29%
Radiotherapy
29%
Rate Measurement
29%
Primary Tumor
29%
Clear Cell Renal Cell Carcinoma (ccRCC)
29%
Ataxia Telangiectasia mutated
29%
Urothelial Carcinoma
29%
Mini
29%
Homologous Recombination Deficiency
29%
Receptor mutations
29%
Failed Repair
29%
In Cancer
29%
Pembrolizumab
29%
Programmed Death-ligand 1 Expression
29%
Egfr
29%
Nucleotide Excision Repair
29%
Head-and-neck Cancer
29%
Metastatic Urothelial Carcinoma
29%
Glomerular Filtration Rate
29%
Personalized Oncology
29%
Genetic Profile
29%
Molecular Signature
29%
Aberrations
23%
Registration Trial
23%
Symptom Score
22%
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
21%
Programmed Death-ligand 1 (PD-L1)
19%
Mutational Signatures
19%
Docetaxel
17%
Clinical Practice Guidelines
17%
Usual Activities
17%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
17%
Clinical Trials
16%
Oncological Treatment
16%
Medicine and Dentistry
Patient-Reported Outcome
88%
Malignant Neoplasm
71%
Bladder Cancer
69%
Symptom
65%
Transitional Cell Carcinoma
62%
Anticarcinogen
61%
Radiation Therapy
39%
Oxidoreductase
37%
Prostaglandin
37%
Base Excision Repair
37%
Clinician
35%
Prostate Cancer
35%
Homologous Recombination
29%
Head and Neck Cancer
29%
Glomerular Filtration Rate
29%
Oncology
29%
Clear Cell Renal Cell Carcinoma
29%
Biological Marker
29%
Adverse Event
23%
Quality of Life
20%
Neoplasm
20%
Technetium-99
19%
Pentetic Acid
19%
Creatinine
19%
Health Care Cost
19%
Bladder Tumor
19%
Cancer Therapy
17%
Docetaxel
17%
Castration Resistant Prostate Cancer
17%
Overall Survival
17%
Epileptic Absence
11%
Cabazitaxel
11%
Solid Malignant Neoplasm
11%
PARP Inhibitor
11%
BRCA1
11%
Abiraterone
11%
Targeted Therapy
11%
Muscle Invasive Bladder Cancer
11%
Irofulven
10%
Kidney Function
9%
Edetate Chromium Cr 51
9%
Radical Surgery
9%
Cisplatin
9%
Invasive Procedure
9%
Urinary Tract Cancer
9%
Non Muscle Invasive Bladder Cancer
9%
Immunotherapy
9%
Plasma Clearance
9%
Cancer Recurrence Treatment
9%
Cancer Epidemiology
9%
